[Form 4] Utah Medical Products Inc Insider Trading Activity

Rhea-AI Filing Summary

Paul O. Richins, a director of Utah Medical Products, sold 100 shares of the company's common stock on 08/25/2025 at $60.34 per share. After the sale he beneficially owns 21,136 shares indirectly, held across a family trust, a personal IRA, his spouse's IRA and his sons' accounts: 18,948 shares in the Richins Family Trust, 1,245 in his spouse's IRA, 443 by his sons and 500 in his own IRA. The Form 4 indicates the filing was made by one reporting person and is signed by Mr. Richins.

Insights

Corporate Governance Expert

TL;DR: A routine small director sale with full disclosure; holdings remain concentrated in family trust.

The reported 100-share sale at $60.34 is immaterial relative to the total beneficial holdings of 21,136 shares and appears as a routine disposition rather than a change in control or large insider divestiture. Disclosure identifies indirect ownership through a family trust and family IRAs, which keeps economic exposure concentrated within Mr. Richins' family. No amendments or other unusual disclosures are present.

Securities Analyst

TL;DR: Minor insider sale reported; transaction size and post-sale holdings indicate no material shift in insider stake.

The transaction code indicates a disposition of 100 shares on 08/25/2025 at $60.34. Post-transaction beneficial ownership is 21,136 shares held indirectly. The sale size is small relative to aggregate holdings and does not suggest a change in insider confidence or material liquidity event. All holdings and the breakdown by account type are disclosed in the filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RICHINS PAUL O

(Last) (First) (Middle)

7043 SOUTH 300 WEST

(Street)

MIDVALE UT 84047

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
UTAH MEDICAL PRODUCTS INC [ UTMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/25/2025		G		100	D	$60.34	21,136	I	See note(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. 1,245 shares held by spouse's IRA; 443 by sons; 500 by own IRA; 18,948 by the Richins Family Trust.

	/s/ Paul O. Richins	08/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did UTMD director Paul O. Richins report?

The Form 4 reports a sale of 100 shares of Utah Medical Products common stock on 08/25/2025 at a price of $60.34 per share.

How many UTMD shares does Paul O. Richins beneficially own after the reported transaction?

Following the reported sale, Mr. Richins beneficially owns 21,136 shares, held indirectly.

How are Paul O. Richins' 21,136 UTMD shares apportioned?

Holdings are broken down as: 18,948 shares in the Richins Family Trust, 1,245 in spouse's IRA, 443 by his sons, and 500 in his own IRA.

Was this Form 4 filed jointly or by a single reporting person?

The filing indicates it was a Form filed by one reporting person and is signed by Paul O. Richins.

What transaction code was used for the sale on the Form 4?

The transaction is reported with code G, indicating a disposition (sale) as listed on the form.